{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:22:45Z","timestamp":1790342565738,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20190809102415054"],"award-info":[{"award-number":["JCYJ20190809102415054"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002704"],"award-info":[{"award-number":["82002704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902588"],"award-info":[{"award-number":["81902588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019230","name":"Wuhan Union Hospital","doi-asserted-by":"publisher","award":["2019xhyn124"],"award-info":[{"award-number":["2019xhyn124"]}],"id":[{"id":"10.13039\/501100019230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFB1303100"],"award-info":[{"award-number":["2017YFB1303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012149","name":"National Key Scientific Instrument and Equipment Development Projects of China","doi-asserted-by":"publisher","award":["81927807"],"award-info":[{"award-number":["81927807"]}],"id":[{"id":"10.13039\/501100012149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jare.2024.04.032","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T18:17:21Z","timestamp":1714587441000},"page":"287-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma"],"prefix":"10.1016","volume":"70","author":[{"given":"Zhihao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-2482","authenticated-orcid":false,"given":"Yuzhong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1321-6954","authenticated-orcid":false,"given":"Gong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2024.04.032_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.jare.2024.04.032_b0015","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2012.475","article-title":"Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer","volume":"307","author":"Tan","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"10021","key":"10.1016\/j.jare.2024.04.032_b0025","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jare.2024.04.032_b0030","first-page":"507","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jare.2024.04.032_b0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4161\/epi.7.2.18973","article-title":"Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells","volume":"7","author":"Kim","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.jare.2024.04.032_b0040","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jare.2024.04.032_b0050","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/1078-0432.CCR-07-4126","article-title":"Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors","volume":"14","author":"Fernando","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2024.04.032_b0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2024.04.032_b0060","first-page":"419","article-title":"Control of angiogenesis by the pericyte: molecular mechanisms and significance","volume":"79","author":"Hirschi","year":"1997","journal-title":"EXS"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0065","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.neo.7900102","article-title":"Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption","volume":"2","author":"Rubenstein","year":"2000","journal-title":"Neoplasia"},{"issue":"10","key":"10.1016\/j.jare.2024.04.032_b0070","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1080\/15548627.2015.1085742","article-title":"Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux","volume":"11","author":"Giuliano","year":"2015","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.jare.2024.04.032_b0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","article-title":"Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA","volume":"29","author":"Qu","year":"2016","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.jare.2024.04.032_b0080","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.21873\/anticanres.16675","article-title":"Renal cell cancer - insights in drug resistance mechanisms","volume":"43","author":"Aweys","year":"2023","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0085","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14737159.2023.2195553","article-title":"The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery","volume":"23","author":"di Meo","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"issue":"21","key":"10.1016\/j.jare.2024.04.032_b0100","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.18632\/aging.102407","article-title":"A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma","volume":"11","author":"Cheng","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"10.1016\/j.jare.2024.04.032_b0105","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","article-title":"Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion","volume":"71","author":"Dirat","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jare.2024.04.032_b0110","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI127201","article-title":"Adipocyte and lipid metabolism in cancer drug resistance","volume":"129","author":"Cao","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169338","article-title":"Differential HDAC1 and 2 recruitment by members of the MIER family","volume":"12","author":"Derwish","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nbt.1759","article-title":"Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes","volume":"29","author":"Bantscheff","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112722","article-title":"MIER3 induces epithelial-mesenchymal transition and promotes breast cancer cell aggressiveness via forming a co-repressor complex with HDAC1\/HDAC2\/Snail","volume":"406","author":"Huang","year":"2021","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.21037\/tcr.2020.01.07","article-title":"MIER3 suppresses the progression of non-small cell lung cancer by inhibiting Wnt\/beta-Catenin pathway and histone acetyltransferase activity","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0135","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1038\/s41598-017-11374-y","article-title":"MIER3 suppresses colorectal cancer progression by down-regulating Sp1, inhibiting epithelial-mesenchymal transition","volume":"7","author":"Peng","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.jare.2024.04.032_b0140","doi-asserted-by":"crossref","first-page":"17489","DOI":"10.18632\/aging.203238","article-title":"HDAC inhibitor Trichostatin A suppresses adipogenesis in 3T3-L1 preadipocytes","volume":"13","author":"Lv","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0145","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12607","article-title":"Melatonin\/PGC1A\/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning","volume":"67","author":"Xiao","year":"2019","journal-title":"J Pineal Res"},{"issue":"10","key":"10.1016\/j.jare.2024.04.032_b0150","article-title":"Tumor cell \u201cSlimming\u201d regulates tumor progression through PLCL1\/UCP1-mediated lipid browning","volume":"6","author":"Xiong","year":"2019","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cmet.2018.06.001","article-title":"Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis","volume":"28","author":"Divakaruni","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cmet.2018.06.002","article-title":"Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation","volume":"28","author":"Raud","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jare.2024.04.032_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107728","article-title":"Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4\/NF-kappaB\/NLRP3 and PGC1a\/SIRT3 pathways","volume":"96","author":"Yao","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.jare.2024.04.032_b0170","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/cvr\/cvab198","article-title":"HDAC1: an environmental sensor regulating endothelial function","volume":"118","author":"Dunaway","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.jare.2024.04.032_b0175","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/jcp.25669","article-title":"SirT3 and p53 Deacetylation in Aging and Cancer","volume":"232","author":"Chen","year":"2017","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.jare.2024.04.032_b0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10565-016-9347-8","article-title":"Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation","volume":"32","author":"Bao","year":"2016","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ctrv.2005.12.006","article-title":"Histone deacetylase inhibitors: multifunctional anticancer agents","volume":"32","author":"Liu","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"10.1016\/j.jare.2024.04.032_b0190","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","article-title":"Histone deacetylase inhibitors and cell death","volume":"71","author":"Zhang","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0195","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.gastro.2016.09.017","article-title":"Estrogen signals through peroxisome proliferator-activated receptor-gamma coactivator 1alpha to reduce oxidative damage associated with diet-induced fatty liver disease","volume":"152","author":"Besse-Patin","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0205","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1038\/s41467-019-13718-w","article-title":"Requirement for p62 acetylation in the aggregation of ubiquitylated proteins under nutrient stress","volume":"10","author":"You","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jare.2024.04.032_b0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2013.08.006","article-title":"Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications","volume":"341","author":"Rydzanicz","year":"2013","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0220","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III Trial","volume":"9","author":"Hakimi","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jare.2024.04.032_b0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","article-title":"Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials","volume":"50","author":"Molina","year":"2014","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.jare.2024.04.032_b0230","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/14712598.2016.1216964","article-title":"The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review","volume":"16","author":"Di Lorenzo","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.jare.2024.04.032_b0235","doi-asserted-by":"crossref","first-page":"355.e11","DOI":"10.1016\/j.urolonc.2019.01.025","article-title":"Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment","volume":"37","author":"Tamma","year":"2019","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.jare.2024.04.032_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041071","article-title":"Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.jare.2024.04.032_b0245","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1039\/C4CS00370E","article-title":"Cancer biomarker detection: recent achievements and challenges","volume":"44","author":"Wu","year":"2015","journal-title":"Chem Soc Rev"},{"issue":"18","key":"10.1016\/j.jare.2024.04.032_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814356","article-title":"Exosomes in the diagnosis and treatment of renal cell cancer","volume":"24","author":"Boussios","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/diseases4010007","article-title":"Renal cell carcinoma: a study through NMR-based metabolomics combined with transcriptomics","volume":"4","author":"Ragone","year":"2016","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.jare.2024.04.032_b0260","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","article-title":"Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future","volume":"19","author":"Van Poppel","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.jare.2024.04.032_b0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14737159.2019.1607729","article-title":"Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma","volume":"19","author":"Lucarelli","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"22","key":"10.1016\/j.jare.2024.04.032_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214360","article-title":"Renal cell carcinoma as a metabolic disease: An update on main pathways, potential biomarkers, and therapeutic targets","volume":"23","author":"di Meo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/j.jare.2024.04.032_b0275","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.18632\/oncotarget.3823","article-title":"Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma","volume":"6","author":"Lucarelli","year":"2015","journal-title":"Oncotarget"},{"issue":"69","key":"10.1016\/j.jare.2024.04.032_b0280","doi-asserted-by":"crossref","first-page":"113502","DOI":"10.18632\/oncotarget.23056","article-title":"The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation","volume":"8","author":"Bianchi","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.jare.2024.04.032_b0285","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.18632\/aging.101685","article-title":"Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma","volume":"10","author":"Lucarelli","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0290","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.jare.2024.04.032_b0295","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.cmet.2021.08.012","article-title":"The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy","volume":"33","author":"Wei","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jare.2024.04.032_b0300","doi-asserted-by":"crossref","first-page":"28932","DOI":"10.1038\/srep28932","article-title":"Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma","volume":"6","author":"Saito","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jare.2024.04.032_b0305","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ajpath.2020.08.008","article-title":"36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells","volume":"190","author":"Bombelli","year":"2020","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.jare.2024.04.032_b0310","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.jare.2024.04.032_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213968","article-title":"MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome","volume":"23","author":"Lucarelli","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jare.2024.04.032_b0320","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of rna synthesis","volume":"51","author":"Allfrey","year":"1964","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jare.2024.04.032_b0325","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","article-title":"Functions and mechanisms of non-histone protein acetylation","volume":"20","author":"Narita","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2024.04.032_b0330","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molcel.2011.04.028","article-title":"Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase","volume":"43","author":"Jiang","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.jare.2024.04.032_b0335","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jprot.2016.10.003","article-title":"Lysine acetylation and cancer: A proteomics perspective","volume":"150","author":"Gil","year":"2017","journal-title":"J Proteomics"},{"issue":"6","key":"10.1016\/j.jare.2024.04.032_b0340","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cmet.2017.09.018","article-title":"Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence","volume":"26","author":"Rios","year":"2017","journal-title":"Cell Metab"},{"issue":"15","key":"10.1016\/j.jare.2024.04.032_b0345","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/ijbs.62236","article-title":"Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer","volume":"17","author":"Ali","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"5","key":"10.1016\/j.jare.2024.04.032_b0350","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-018-0158-8","article-title":"SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1\/2","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:56:34Z","timestamp":1778835394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123224001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":70,"alternative-id":["S2090123224001772"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2024.04.032","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2024.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}